References
- Lareau SC, Fahy B, Meek P, Wang A. Chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 2019;199:1–P2.
- Global Initiative for Chronic Obstructive Lung Disease Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease; 2020.
- Pezzuto A, Spoto C, Vincenzi B, Tonini G. Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level. J Comp Eff Res. 2013;2:335–343.
- Song Q, Zhao YY, Zeng YQ, et al. The characteristics of airflow limitation and future exacerbations in different GOLD groups of COPD patients. Int J Chronic Obstr Pulm Dis. 2021;16:1401–1412.
- Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;6:957–963.
- Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009;4:203–223. doi:10.2147/copd.s3385
- Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores. BMC Pulm Med. 2011;11:42. doi:10.1186/1471-2466-11-42
- Hayata A, Minakata Y, Matsunaga K, Nakanishi M, Yamamoto N. Differences in physical activity according to mMRC grade in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2203–2208.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117.
- Deveci S, Deveci F, Açik Y, Ozan A. The measurement of exhaled carbon monoxide in healthy smokers and non smokers. Respir Med. 2004;98:551–556.
- Laszlo G. Standardization of lung function testing: helpful guidance from the ATS/ERS Task Force. Thorax. 2006;61:744–746.
- Kershbaum A, Bellet S, Dickstein ER, Feinbergl J. Effect of cigarette smoking and nicotine on serum free fatty acids based on a study in the human subject and the experimental animal. Circ Res. 1961;9:631–638. doi:10.1161/01.res.9.3.631.
- Forey BA, Fry JS, Lee PN, Thornton AJ, Coombs KJ. The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes. Biomark Res. 2013;1(1):26. doi:10.1186/2050-7771-1-26.
- Mirza S, Clay RD, Koslow MA. Scanlon PD2 COPD Guidelines: a Review of the 2018 GOLD Report. Mayo Clin Proc. 2018;93:1488–1502.
- Rennard SI, Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:878–883. doi:10.1513/pats.200804-035QC
- Pezzuto A, Lionetto L, Ricci A, Simmaco M, Borro M. Inter-individual variation in CYP2A6 activity and chronic obstructive pulmonary disease in smokers: perspectives for an early predictive marker. Biochim Biophys Acta Mol Basis Dis. 2021;1867(1):165990.
- Maci E, Comito F, Frezza AM, Tonini G, Pezzuto A. Lung nodule and functional changes in smokers after smoking cessation short-term treatment. Cancer Investig. 2014;32:388–393.
- Pezzuto A, Stellato M, Catania G, et al. Short term benefit of smoking cessation along with glycopyrronium on lung function and respiratory symptoms in mild COPD patients: a retrospective study. J Breath Res. 2018;12:046007.
- Polosa R. Cessation of smoking in COPD: a reality check. Intern Emerg Med. 2021;16:2029–2030. doi:10.1007/s11739-021-02740-w
- Wohnhaas CT, Gindele JA, Kiechle T, et al. Cigarette smoke specifically affects small airway epithelial cell populations and triggers the expansion of inflammatory and squamous differentiation associated basal cells. Int J Mol Sci. 2021;22(14):7646. doi:10.3390/ijms22147646.
- Churg A, Tai H, Coulthard T, Wang R, Wright JL. Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall. Am J Respir Crit Care Med Churg. 2006;174(12):1327–1334. doi:10.1164/rccm.200605-585OC.
- Tashkin DP. Smoking cessation in COPD: confronting the challenge. Intern Emerg Med. 2021;16:545–547.
- Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, for the Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64–71.
- Ghosh B, Gaike AH, Pyasi K, et al. Bacterial load and defective monocyte-derived macrophage bacterial phagocytosis in biomass smoke-related COPD. Eur Respir J. 2019;53(2):1702273. doi:10.1183/13993003.02273-2017.
- Vicol C, Buculei I, Melinte OE, et al. The lipid profile and biochemical parameters of COPD patients in relation to smoking status. Biomedicines. 2022;10(11):2936. doi:10.3390/biomedicines10112936.
- Freyberg J, Landt EM, Afzal S, Nordestgaard BG, Dahl M. Low-density lipoprotein cholesterol and risk of COPD: Copenhagen general population study. ERJ Open Res. 2023;9(2):00496–2022.
- He BM, Zhao SP, Peng ZY. Effects of cigarette smoking on HDL quantity and function: implications for atherosclerosis. J Cell Biochem. 2013;114(11):2431–2436.
- Zhang C, Zhu Z. ”Associations among vitamin D, tobacco smoke, and hypertension: a cross-sectional study of the NHANES 2001-2016” by Wu et al. Hypertens Res. 2023;46(6):1615.